Infinitesima Pharma and NeuAngel Biopharmaceuticals Enter into Over RMB 20 Million AI-Driven CNS Drug Discovery Collaboration
Inflygent Pharmaceutical AI
AI+ New Drug R&D Company
NeuAngel Biopharma
--
Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted must be authorized.
PharmaCircle learned that: On January 28, Inflygent Pharmaceutical AI and NeuAngel Biopharma signed a cooperation agreement. Both parties will carry out multi-target small molecule drug co-development in the field of CNS diseases. According to the terms of the agreement, Inflygent Pharmaceutical AI will utilize its ownPharmaMindDrug Design Platform, Focused on by Enze BioCNSDisease Field ConductAIMulti-target drug design and development,This Technical Service ContractTotal ExceedsRMB 20 million, in the previous cooperation between the two parties, Inflygent Pharmaceutical AI had utilized its self-developedTopTargetsThe platform helped Enze Bio determine a combination scheme for multiple targets.
NeuAngel Biopharmaceuticals focuses on developing and promoting the best therapies for the treatment of Alzheimer's disease psychosis, while also being committed to treating a broader range of dementia-related psychiatric conditions.
